Very true, it doesn’t help when we are looking a
Post# of 157752
I think I’m running out of comments so I’ll ask this here.
I know I won’t get a straight answer, but Dr NP brought up unmet medical need for the severe trial, however he appeared to brush over the mild to moderate? I’ll have to rewatch.
Anyways my question is could we get EAU on the Phase 2 MM trial then approval for phase 3? I don’t think that’s a bad thing and more likely? I think NP basically said he doesn’t know. Maybe someone can shed some light on possible outcomes again. Having a hard time putting this together.
Also does this mean we will still be able to get a readout on the severe trial as will as the MM at the same time, thus the request for the information to be released.
Some clarification would be great.


CytoDyn Inc (CYDY) Stock Research Links
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://zenodo.org/records/17290045?token=eyJ...UkeT_EvKIQ
https://firegatebiotech.com/2025
https://zenodo.org/records/17291133?token=eyJ...kN7msthgMA
— Jeremiah 51:36